ライフサイエンスコーパス: 6-mercaptopurine

1 ncristine, L-asparaginase, methotrexate, and 6-mercaptopurine.

2 ffectiveness of the immuno-suppressive agent 6-mercaptopurine.

3 es S-methylation of thiopurine drugs such as 6-mercaptopurine.

4 mprove on azathioprine but responded well to 6-mercaptopurine.

5 nd 1.27 (95% CI, 0.48-3.39) for azathioprine/6-mercaptopurine.

6 aintenance with ATRA, oral methotrexate, and 6-mercaptopurine.

7 bits a decreased V max and increased K m for 6-mercaptopurine.

8 ome mice were pretreated with leflunomide or 6-mercaptopurine.

9 leukemia (ALL) includes prednisone and oral 6-mercaptopurine.

10 e dose, and all patients received daily oral 6-mercaptopurine.

11 xamined the efficacy of dexamethasone and IV 6-mercaptopurine.

12 se, 11), whereas 6-thio NHD(+) (nicotinamide 6-mercaptopurine 5'-dinucleotide, 17) generates a cyclic

13 of their respective substrates, azathioprine/6-mercaptopurine, 5-fluorouracil and sulindac.

14 Although the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are wel

15 The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for

16 The thiopurines azathioprine and 6-mercaptopurine (6-MP) are effective immune modulators

17 Azathioprine (AZA) and 6-mercaptopurine (6-MP) are used in pediatric patients w

18 Azathioprine and its metabolite 6-mercaptopurine (6-MP) are well established immunosuppr

19 6-Mercaptopurine (6-MP) is a nucleobase analog used in t

20 Clinical experience suggests that 6-mercaptopurine (6-MP) is effective therapy for childre

21 iated AICAR production, or administration of 6-mercaptopurine (6-MP), a clinically approved inhibitor

22 To evaluate potential toxicity of 6-mercaptopurine (6-MP), we reviewed the records of 485

23 among patients treated with azathioprine or 6-mercaptopurine (6-MP).

24 of immunomodulators [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newer biologic agents (infl

25 classified into a high DI phenotype (either 6-mercaptopurine [6-MP] or methotrexate [MTX] DI >=110%

26 6-Mercaptopurine, 6-thioguanine and dasatinib are three

27 oped for the simultaneously determination of 6-mercaptopurine, 6-thioguanine and dasatinib for the fi

28 ed for the selective and precise analysis of 6-mercaptopurine, 6-thioguanine and dasatinib in pharmac

29 data revealed that the electro-oxidation of 6-mercaptopurine, 6-thioguanine and dasatinib is facilit

30 r at pH 8.0, the oxidation peak currents for 6-mercaptopurine, 6-thioguanine and dasatinib were found

31 Compared with 6-mercaptopurine, 6-thioguanine causes excess toxicity w

32 tabolites of three clinically useful agents (6-mercaptopurine, 6-thioguanine, and Abacavir) can inhib

33 Variability in prescribed doses of 6-mercaptopurine (6MP) and lack of adherence to a 6MP tr

34 6-Mercaptopurine (6MP) and methotrexate are the backbone

35 Adequate exposure to oral 6-mercaptopurine (6MP) during maintenance therapy for ch

36 r maintenance phase that includes daily oral 6-mercaptopurine (6MP).

37 igned either 6-thioguanine (750 patients) or 6-mercaptopurine (748 patients) during interim maintenan

38 + azathioprine were superior to azathioprine/6-mercaptopurine: adalimumab (OR, 2.9; 95% CrI, 1.6-5.1)

39 In contrast, pretreatment of mice with 6-mercaptopurine, an inhibitor of de novo purine synthes

40 nd conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL

41 the MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purin

42 ved in the metabolism of thiopurines such as 6-mercaptopurine and 6-thioguanine.

43 yhan syndrome, the activator of the prodrugs 6-mercaptopurine and allopurinol, and a target for antip

44 (6-TP) medications, including 6-thioguanine, 6-mercaptopurine and azathioprine, commonly used for imm

45 The immunosuppressive agents, azathioprine, 6-mercaptopurine and cyclosporine A, are compatible with

46 hylguanine, 8-azaguanine, 6-thioguanine, and 6-mercaptopurine and do not recognize any of the PurP li

47 1-year treatment period with the following: 6-mercaptopurine and metronidazole [6MP/met] (comparator

48 pite the extensive clinical use and study of 6-mercaptopurine and other purine analogues, the cellula

49 ing some of the antiproliferative effects of 6-mercaptopurine and potentially implicate Nurr1 as a mo

50 ing setons, antibiotics, and azathioprine or 6-mercaptopurine and, in many cases, infliximab.

51 standard dose of thiopurine (azathioprine or 6-mercaptopurine), and patients homozygous for a variant

52 Thiopurines including 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine are effective antican

53 urine drugs, including 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine, are widely employed

54 riptions for 5-aminosalicylates azathioprine/6-mercaptopurine, and corticosteroids were extracted fro

55 icians in optimizing therapeutic response to 6-mercaptopurine, and in identifying individuals at incr

56 95% CI, 1.3-1.9]), and exposure to platinum, 6-mercaptopurine, and intrathecal chemotherapy, and a lo

57 therapy followed by prednisone, vincristine, 6-mercaptopurine, and methotrexate (POMP) maintenance ch

58 It is derived from 6-mercaptopurine, and these two drugs are often used int

59 cytarabine/etoposide; high-dose methotrexate/6-mercaptopurine; and daunorubicin, vincristine, prednis

60 Azathioprine and 6-mercaptopurine are the standard maintenance therapies

61 and Arg221, the only polar amino acids near 6-mercaptopurine, are highlighted as possible participan

62 receptor Nurr1, interestingly, we identified 6-mercaptopurine as a specific activator of this recepto

63 A resolution and the chemotherapeutic agent 6-mercaptopurine at 2.6 A resolution have been determine

64 n of asparagine synthetase or treatment with 6-mercaptopurine attenuated the increased function of GL

65 rential 6-methylmercaptopurine production on 6-mercaptopurine/azathioprine (odds ratio, 3.0; 95% CI,

66 6-Mercaptopurine/azathioprine alone and the addition of

67 corticosteroids alone, 52 patients receiving 6-mercaptopurine/azathioprine alone or with corticostero

68 ry who were receiving corticosteroids and/or 6-mercaptopurine/azathioprine before surgery compared wi

69 ry bowel disease receive corticosteroids and 6-mercaptopurine/azathioprine during elective bowel surg

70 e adjusted odds ratio for patients receiving 6-mercaptopurine/azathioprine for any and major infectio

71 urine/azathioprine alone and the addition of 6-mercaptopurine/azathioprine for patients receiving cor

72 6-mercaptopurine/azathioprine is effective in IBD patien

73 tients receiving neither corticosteroids nor 6-mercaptopurine/azathioprine.

74 hat an active site loop becomes ordered upon 6-mercaptopurine binding.

75 c acid decreases V max and increases K m for 6-mercaptopurine but not K m for S-adenosyl- l-methionin

76 toxic effects of thiopurine prodrugs such as 6-mercaptopurine by methylating them in a reaction using

77 ressant and anticancer drugs azathioprine or 6-mercaptopurine contains 6-thioguanine (6-TG).

78 d assignment was for daily oral or weekly IV 6-mercaptopurine during consolidation.

79 minosalicylate drugs as well as azothiaprine/6-mercaptopurine during pregnancy.

80 (steroids and/or cyclosporine, azathioprine, 6-mercaptopurine, FK-506, methotrexate) were identified

81 ion therapy with the same combinations, plus 6-mercaptopurine, for 12 months total treatment.

82 aptopurine; however, patients assigned to IV 6-mercaptopurine had decreased survival after relapse.

83 6-mercaptopurine has been a standard component of long-t

84 The thiopurines azathioprine and 6-mercaptopurine have been extensively prescribed as imm

85 EFS was similar with oral or IV 6-mercaptopurine; however, patients assigned to IV 6-mer

86 conferred comparable levels of resistance to 6-mercaptopurine in B-ALL cells both in vitro and in viv

87 icylates and 24.6% discontinued azathioprine/6-mercaptopurine in early pregnancy.

88 report our experience with azathioprine and 6-mercaptopurine in patients with microscopic colitis.

89 st potential benefit from the earlier use of 6-mercaptopurine in T-ALL therapy or the development of

90 N = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab,

91 In addition, 6-mercaptopurine is a clinically important pro-drug that

92 The purine anti-metabolite 6-mercaptopurine is one of the most widely used drugs fo

93 munosuppressant thiopurines, azathioprine or 6-mercaptopurine, is associated with acute skin sensitiv

94 purine methyl transferase and measurement of 6-mercaptopurine metabolites appear to be valuable for m

95 Studies of azathioprine and 6-mercaptopurine metabolites will make it easier and saf

96 ; 95% CI, 1.17-2.58; P = .006), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.6

97 rapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inh

98 of vincristine, adriamycin, prednisone, and 6-mercaptopurine (MP) and after continuous infusion of h

99 substitution of oral 6-thioguanine (TG) for 6-mercaptopurine (MP) and triple intrathecal therapy (IT

100 Recent studies of azathioprine/6-mercaptopurine, nitroimidazole antibiotics, and inflix

101 lower risk of isolated CNS relapse than did 6-mercaptopurine (odds ratio [OR] 0.53, 95% CI 0.30-0.92

102 ids (OR, 3.4; 95% CI, 1.8-6.2), azathioprine/6-mercaptopurine (OR, 3.1; 95% CI, 1.7-5.5), and inflixi

103 dard, second-line (mycophenolate mofetil and 6-mercaptopurine) or third-line (tacrolimus or cyclospor

104 exposed to 5-aminosalicylates, azathioprine/6-mercaptopurine, or corticosteroids during their first

105 purine regulation of Nurr1 demonstrates that 6-mercaptopurine regulates Nurr1 through a region in the

106 A detailed analysis of 6-mercaptopurine regulation of Nurr1 demonstrates that 6

107 tations in NT5C2 and a common determinant of 6-mercaptopurine resistance.

108 de, was a substrate, and it was converted to 6-mercaptopurine ribonucleotide.

109 metabolites, thiouric acid (TU) and 2-amino-6-mercaptopurine riboside (6-TGR).

110 6-mercaptopurine should remain the thiopurine of choice

111 A metabolite of AZA, 6-mercaptopurine, still possessed this antiviral effect,

112 F inhibitor in combination with azathioprine/6-mercaptopurine therapy (odds ratio [OR], 1.74; 95% CI,

113 inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azat

114 S-adenosyl- l-homocysteine and the substrate 6-mercaptopurine, to 1.8 and 2.0 A resolution, respectiv

115 eived 30 courses of maintenance therapy with 6-mercaptopurine, vincristine, methotrexate, and prednis

116 alternating blocks of three cycles of POMP (6-mercaptopurine, vincristine, methotrexate, and prednis

117 Maintenance therapy with dose-reduced POMP (6-mercaptopurine, vincristine, methotrexate, and prednis

118 ance chemotherapy with oral methotrexate and 6-mercaptopurine was continued for 30 months.

119 wn that 6-thioguanine is more effective than 6-mercaptopurine, we compared the efficacy and toxicity

120 The prodrugs azathioprine and 6-mercaptopurine, which are well-established anticancer

121 rednisone and for intravenous (IV) over oral 6-mercaptopurine, which remain to be validated.

122 atient response to the chemotherapeutic drug 6-mercaptopurine, with some model parameters being patie

123 s with NT5C2 mutations are chemoresistant to 6-mercaptopurine yet show impaired proliferation and sel